A phase II study of irinotecan in patients with advanced hepatocellular carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Biomarkers, Tumor
  • Genomic Instability
  • Pancreatic Neoplasms
  • Precision Medicine

abstract

  • Irinotecan had modest activity in advanced hepatocellular cancer. Toxicity was substantial, presumably reflecting impaired underlying liver function or poor ability to metabolize and eliminate the drug. The current study indicated that continued new therapy assessment is warranted for this disease.

publication date

  • January 2001

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(20010101)91:1<101::AID-CNCR13>3.0.CO;2-K

PubMed ID

  • 11148565

Additional Document Info

start page

  • 101

end page

  • 5

volume

  • 91

number

  • 1